Celsion Corporation, a US developer of cancer treatments, has announced that Edwin De Wit will join the company as Senior Vice President and Head of Medical, Europe.
Dr De Wit brings more than 20 years of experience in clinical operations and research in the pharma and biotech industry to the New Jersey-based firm, having previously worked at Onyx Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer.
'Dr De Wit's international experience and expertise in pharmaceutical strategy and in the design and execution of large oncology programmes will be invaluable as he establishes broad oversight of Celsion's interests in Europe,' said Michael Tardugno, Celsion's Chairman, President and Chief Executive.
Most recently, Dr De Wit was Head of Medical, Europe & Middle East and Africa at Onyx Pharmaceuticals, a subsidiary of Amgen, focused on developing cancer therapeutics. Prior to Onyx, he was Executive Director of Oncology Clinical Research at Boehringer Ingelheim from 2008–2012 where he was responsible for the development of novel anti-cancer agents in various stages of development. He also held leadership roles in the area of Oncology Clinical Development at Bristol-Myers Squibb from 2005–2008 and at Pfizer from 2002–2005, after having spent more than ten years in clinical operations roles at Smithkline Beecham, Ferring Pharmaceuticals and Vitaresc Biotech.
